Hormones and Cardiovascular Disease
Director: Pierre-Yves Scarabin

 

Hormones and Cardiovascular Disease
Director: Pierre-Yves Scarabin

 

Hormones and Cardiovascular Disease
Director: Pierre-Yves Scarabin

 

We updated previous meta-analyses of venous thromboembolism (VTE) risk in postmenopausal hormone therapy (HT) users, focusing on the route of estrogen administration, hormonal regimen and progestogen type. Based on seven observational studies, this meta-analysis confirms the safety of transdermal estrogens whereas oral estrogens increase VTE risk. In women using opposed estrogen, results are highly heterogeneous due to important differences between the molecules of progestogen. In transdermal estrogen users, there was no change in VTE risk in women using micronized progesterone whereas norpregnane derivatives are associated with increased VTE risk. Among women using opposed oral estrogen, there was higher VTE risk in women using medroxyprogesterone acetate than in those using other progestins. These data have been published in Climacteric. They emphasize the safety advantage of transdermal estrogen combined with progesterone and they support the current evidence-based recommendations on HT, especially in women at high VTE risk.

© Esther 2019